Clinical Trial Update: Study of Vintafolide (MK-8109, EC145) for the Treatment of Recurrent or Refractory Solid Tumors (MK-8109-006, EC-FV-01) [Phase 1]

View source ↗

Summary

Phase 1 study of vintafolide (MK-8109, EC145) for recurrent or refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Vintafolide (MK-8109 / EC145)

Snippet

Sponsor: Endocyte | Conditions: Cancer | Phase 1 | Status: COMPLETED